From: Owner of many system processes [daemon@pharmalicensing.com] on
behalf of editors@pharmalicensing.com
Sent: Friday, December 21, 2001 2:05 PM
To: pl-update@atlas.pharmalicensing.com
Subject: pharmalicensing update: Nerry Christmas - Aventis Pharma -
Respiratory Technology, SYNT:EM, Healthpoint, Rhein Biotech, Global
Technologies, Aptus Genomics, University of Maryland Biotechnology Inst
pharmalicensing.com update -- 21 December 2001
Welcome to the weekly bulletin from pharmalicensing.com, the centre of
online pharmaceutical/biotech licensing and business development.
For details of advertising, reproduction and unsubscribing, see the end
of this newsletter.
*******************************************************************
Everyone at pharmalicensing would like to wish all our readers:
Merry Christmas and a Happy New Year
Joyeux Noel et Bonne Annee
Frohe Weihnachten und ein Gutes Neues Jahr
Buon Natale e Felice Anno Nuovo
Felices Navidades y Buen Ano Nuevo
*******************************************************************
| ** Drug Delivery Technologies: Innovations and market challenges **
| http://www.pjbpubs.com/scriprep/bs1086.htm
|
| The definitive report on global trends in innovative drug delivery
| technologies....including forecasts to 2005
|
| For further informaation and to order your copy:
| http://www.pjbpubs.com/scriprep/bs1086.htm
-----------------------------------------------------------------------
| Need to know the latest news in pharma/biotech partnering?
|
| Pharmalicensing Update - Business Development Report
|
| December issue out now - view the contents page
|
| http://pharmalicensing.com/features/disp/1003401396_3bceb0b4c7eae
|
| Our new monthly report will keep you up to date on the latest
| partnering developments and opportunities.
|
| http://pharmalicensing.com/features/disp/1003401396_3bceb0b4c7eae
|
| Subscribe today to receive 15 issues for the price of 12 !!
| Offer ends 31st December 2001
-----------------------------------------------------------------------
In this issue:
* featured articles: A Tour around Septic Shock, Patenting Human Genes
and other Parts of the Human Body under EC Biotechnology Directive
* featured companies: Aventis Pharma - Respiratory Technology,
SYNT:EM, Healthpoint, Rhein Biotech, Global Technologies,
Aptus Genomics, University of Maryland Biotechnology Institute,
Light Sciences, Merz Pharmaceuticals, Endocrine Transplant,
Medinnova
* featured out-licensing opportunities: Aptus Genomics,
Light Sciences, Medinnova, Pharmalink, Rhein Biotech SYNT:EM
* featured in-licensing requirements: Andrx Corporation, Pharmalink
* featured outsource services: Vision In Business, Pharmalaw,
Wainwright, Hovione, Health Decisions
* featured jobs: Isis Innovation, Medic Group
* company news: Astex Technology, Athersys, DFB Pharmaceuticals,
DPT Laboratories Endocrine Transplant, Global Technologies, Pharmexa
* industry news
* featured conferences: IBC Life Sciences, RauCon .Com concepts +
competence, Worldwide Business Research
Please feel free to circulate this newsletter to colleagues, or
encourage them to sign up at http://pharmalicensing.com/
-----------------------------------------------------------------------
| Financial Terms and Royalty Rates in Pharma Deals 2001
| - Order now and receive a 5% discount
|
| - full contents details at:
| http://www.pharmalicensing.com/features/disp/1002219491_3bbca7e33e05d
|
| Financial Terms and Royalty Rates in Pharma Deals 2001
| - published January 2002
|
| The report will provide an invaluable reference source for deal-
| making in the future, packed with extensive primary research data
| view the contents page at the bottom of the webpage at:
| http://www.pharmalicensing.com/features/disp/1002219491_3bbca7e33e05d
|
| The report is priced at: UKP595/US$895.
|
| If you order now, you will be given a 5% discount,
| reducing the price to just UKP565/US$850.
| (academic rate - UKP445 / US$720)
| http://www.pharmalicensing.com/features/disp/1002219491_3bbca7e33e05d
|
| This offer applies to orders received before 31st December 2001
-----------------------------------------------------------------------
FEATURE ARTICLES
Essential reading from industry experts.
A Tour around Septic Shock
http://pharmalicensing.com/features/disp/1006772425_3c0220c99cdbd
Sepsis is an especially difficult condition for even highly skilled
ICU staff to manage. Apart from being serious in its own right, many
people who develop sepsis are already weakened by illness or injury.
So it's unlikely that mortality will ever be eliminated in this
vulnerable group. But the new drugs mentioned in this tour should
markedly improve outcomes in this deadly disease.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patenting Human Genes and other Parts of the Human Body under EC
Biotechnology Directive
http://pharmalicensing.com/features/disp/1008262393_3c18dcf915ce1
The EC Directive on the legal protection of biotechnological
inventions (1998) is more than just a normative framework for
patenting biological substances. After an uphill struggle against
fierce opposition to 'patents on life', the Directive signifies a
breakthrough in a yearlong stalemate.
-----------------------------------------------------------------------
FEATURED COMPANIES
We're pleased to announce the following profiles, recently added to our
company directory:
Aventis Pharma - Respiratory Technology
http://pharmalicensing.com/company/dc/3258
Respiratory Product Development
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SYNT:EM
http://pharmalicensing.com/company/dc/3391
Synt:em discovers and develops novel drug candidates using its
Pep:trans and Acti:map(tm) technologies.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Healthpoint, Ltd., a DFB Pharmaceuticals Company
http://pharmalicensing.com/company/dc/2807
Healthpoint focuses on the research, development, and marketing of
branded pharmaceuticals, over the counter drugs, and medical devices
worldwide.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rhein Biotech GmbH
http://pharmalicensing.com/company/dc/3361
Rhein Biotech GmbH - the Technology Centre of the Rhein Biotech Group
- is dedicated to the development of recombinant gene expression and
full process technologies for the production of proteins.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Global Technologies
http://pharmalicensing.com/company/dc/3348
Provides information solutions to the pharmaceutical and healthcare
industries
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Aptus Genomics, Inc.
http://pharmalicensing.com/company/dc/3357
Aptus is a biotechnology company with a unique competitive advantage
in GPCR-based drug discovery.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
University of Maryland Biotechnology Institute (UMBI)
http://pharmalicensing.com/company/dc/2353
The Business Development Office for the University of Maryland
Biotechnology Institute
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Light Sciences Corporation
http://pharmalicensing.com/company/dc/3356
Development of integrated treatment solutions to induce cell death in
diseased and abnormally proliferating tissues. Photodynamic therapy
platforms directed to cancer, eye and cardiovascular disease
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Merz Pharmaceuticals
http://pharmalicensing.com/company/dc/3354
Merz Pharmaceuticals: Market leader in antidementia prescription
drugs, antiparkinson, liver and scar therapy. Merz Consumer Care:
Self-medication products and dermatopharmaceutical products.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Endocrine Transplant, Inc
http://pharmalicensing.com/company/dc/3353
The company has patented the use of an established drug for immune
modulation therapy of inhalation/Systemic anthrax
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Medinnova SF
http://pharmalicensing.com/company/dc/2909
Medinnova connects industry with the Norwegian National Hospital.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Get news of new companies as soon as they are posted: use our email
alerts: log in and choose "Email alerting" from your User Centre
Want to exhibit your company? Visit http://pharmalicensing.com/sales/
or send enquiries to sales@pharmalicensing.com
-----------------------------------------------------------------------
OUT-LICENSING OPPORTUNITIES
New and exciting technology opportunities from our global database.
Acti:Map(tm) Computational Drug Discovery/Optimisation Technology
(SYNT:EM)
http://pharmalicensing.com/licensing/displicopp/1485
A property-based Pharma-informatics approach that starts from a small
learning set of active/inactive molecules and renders possible the
optimisation of leads or the discovery of completely novel compounds
with increased biological activity
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pep:trans Drug Delivery Technology
(SYNT:EM)
http://pharmalicensing.com/licensing/displicopp/1484
Pep:trans enables the delivery of small molecules, peptides, proteins
(including antibodies), , oligonucleotides and DNA fragments across
the blood brain barrier (BBB) into the CNS and across cell membranes
into cells.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Nefecon - New patented treatment for IgA nephropathy (IgAn).
(Pharmalink AB)
http://pharmalicensing.com/licensing/displicopp/1447
New patented treatment for , IgA nephropathy (IgAn).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Xepol - New patented treatment for Post-Polio Syndrome
(Pharmalink AB)
http://pharmalicensing.com/licensing/displicopp/1446
IV treatment for Post-Polio Syndrome
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Universal Blood Tube
(Rhein Biotech GmbH)
http://pharmalicensing.com/licensing/displicopp/1482
Platform Technology, Blood & Clotting
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hansenula polymorpha Yeast Expression Technology
(Rhein Biotech GmbH)
http://pharmalicensing.com/licensing/displicopp/1480
in-house license for Hansenula polymorpha as expression system for
recombinant proteins
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hansenula Derived r-Hirudin
(Rhein Biotech GmbH)
http://pharmalicensing.com/licensing/displicopp/1481
Platform Technology, Blood & Clotting
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Bioethanol Production
(Rhein Biotech GmbH)
http://pharmalicensing.com/licensing/displicopp/1483
Starch hydrolysing yeast producing bioethanol
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
A new method for diagnosis of atheromatosis
(Medinnova SF)
http://pharmalicensing.com/licensing/displicopp/697
A laboratory test for determination of blood platelet activation
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Light Sciences System for Intratumoral Photodynamic Therapy
(Light Sciences Corporation)
http://pharmalicensing.com/licensing/displicopp/1478
A fully integrated intratumoral photodynamic therapy (PDT) system for
solid tumors
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
AptuScreen
(Aptus Genomics, Inc.)
http://pharmalicensing.com/licensing/displicopp/1479
AptuScreen is a proprietary, high throughput screening assay that
measures cAMP formation.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Do you want to exhibit your technology to thousands of licensing and
business development professionals? Pharmalicensing is the leading
online forum for promoting your opportunities. Send email to
sales@pharmalicensing.com to find out about our no-hidden-fees
promotion packages.
-----------------------------------------------------------------------
IN-LICENSING REQUIREMENTS
Licensing requirements from companies featured in our global database.
Cardiology, gastroenterology, and pain products (US, primary care, and
late-stage)
(Andrx Corporation)
http://pharmalicensing.com/licensing/displicopp/1449
Andrx is interested in exploring licensing/collaborative product
opportunities in cardiology, gastroenterology, and pain (US, primary
care, and late-stage).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hospital pharmaceuticals
(Pharmalink AB)
http://pharmalicensing.com/licensing/displicopp/1472
Pharmalink is seeking In-licensing hospital pharmaceutical products
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cefuroxim, Kloxacillin and Besypenicillin
(Pharmalink AB)
http://pharmalicensing.com/licensing/displicopp/1471
Cefuroxim, Kloxacillin, Besypenicillin Pharmalink is seeking
Cefuroxim, Kloxacillin and Besypenicillin for the Swedish and Nordic
market.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Do you want to advertise your technology needs to thousands of
business development professionals? Pharmalicensing is the leading
online forum for reaching innovators worldwide. Send email to
sales@pharmalicensing.com to find out about our no-hidden-fees
promotion packages.
-----------------------------------------------------------------------
ADVERTISEMENT
| ** Scrip's Practical Guide to Pharmaceutical Licensing **
| http://www.pjbpubs.com/scriprep/bs1111.htm
|
| A comprehensive guide to in and out-licensing and managing
| successful deals
| Includes: Licensing strategy, preparation of dossiers, support
| material, product evaluation, negotiation of term sheets and
| contracts
|
| Available in hardcopy or electronic format - order now!
| http://www.pjbpubs.com/scriprep/bs1111.htm
-----------------------------------------------------------------------
FEATURED OUTSOURCE SERVICES
Second Generation CRO
(Health Decisions)
http://pharmalicensing.com/solutions/disp/3011?svc=746
Health Decisions is a contract clinical development organisation with
an emphasis on strategic planning and the use of electronic study
management tools to reduce the time required for product development
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Regulatory and Liability matters
(PharmaLaw)
http://pharmalicensing.com/solutions/disp/3266?svc=715
Whilst day-to-day regulatory work, dossier and technical file
preparation is best done by regulatory professionals, companies may
also want to obtain a legal view on whether their position on a
particular issue is justified. Using a lawyer to challenge the
regulator and the regulatory status quo can provide useful support in
such a dispute
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Licensing Consultancy
(Wainwright)
http://pharmalicensing.com/solutions/disp/2190?svc=724
Wainwright Associates have the skills and knowledge of the market not
only to find partners for in- and out-licensing but also to provide
full technical and regulatory due diligence on product dossiers for
suitability for registration and marketing
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chemical process research and development
(Hovione)
http://pharmalicensing.com/solutions/disp/2260?svc=739
Hovione has carved a niche for itself synthesizing complex Active
Pharmaceutical Ingredients (APIs) and Intermediates that are highly
regulated. Our products are at the pinnacle of the Fine Chemicals
Industry
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Do you want to reach thousands of business development professionals
with your services and expertise?
Send email to sales@pharmalicensing.com to find out more
information about advertising your services with Pharmalicensing.
-----------------------------------------------------------------------
FEATURED JOB VACANCIES
Career opportunities in licensing and business development.
Project Managers - Physical and Life Sciences (Isis Innovation Ltd)
Number of posts: 2
Salary: Commensurate with ability and experience.
Location: Summertown, Oxford
Full details of post available online at:
http://pharmalicensing.com/company/dispjob/1008602242_3c1e0c82213a1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chief Technology Officer (Medic Group Inc.)
Number of posts: 1
Location: Medic Group, 3629 Highway P, Jackson, Wisconson
53037, USA
Full details of post available online at:
http://pharmalicensing.com/company/dispjob/1008321838_3c19c52edac52
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Do you want to reach thousands of licensing and business development
professionals? Send email to sales@pharmalicensing.com to find out
more information about advertising jobs with Pharmalicensing.
-----------------------------------------------------------------------
COMPANY NEWS
Read about the latest developments from Pharmalicensing exhibitors.
DPT Completes Acquisition of the Assets of West Pharmaceutical Services
Lakewood, Inc.
(DFB Pharmaceuticals, Inc., 17 December)
http://pharmalicensing.com/company/disprelease/1008622940_3c1e5d5c32eb4
DPT Laboratories, Ltd., a premier, full-service developer and
contract manufacturer of over-the-counter and prescription
pharmaceuticals, announced today it has completed the acquisition of
the assets of West Pharmaceutical Services Lakewood, Inc.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
DPT Completes Acquisition of the Assets of West Pharmaceutical Services
Lakewood, Inc.
(DPT Laboratories, Ltd., a DFB Pharmaceuticals Company, 17 December)
http://pharmalicensing.com/company/disprelease/1008622155_3c1e5a4b4ad43
DPT Laboratories, Ltd., a premier, full-service developer and
contract manufacturer of over-the-counter and prescription
pharmaceuticals, announced today it has completed the acquisition of
the assets of West Pharmaceutical Services Lakewood, Inc.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pharmexa in AutoVac cancer license option
(Pharmexa A/S, 17 December)
http://pharmalicensing.com/company/disprelease/1008591733_3c1de375e4e80
Pharmexa has signed an agreement with Lexigen Pharmaceuticals Corp.,
USA (subsidiary of Merck KGaA, Darmstadt, Germany) regarding a
therapeutic cancer vaccine (pharmaccine)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Astex solves first structure of a human cytochrome P450, a key enzyme
in drug metabolism and toxicity.
(Astex Technology Ltd, 17 December)
http://pharmalicensing.com/company/disprelease/1008687550_3c1f59be70156
Astex Technology, the structure-based drug discovery company
pioneering the use of high throughput X-ray crystallography (HTX)
technology, today announced that it has solved the first
3-dimensional crystal structure of a human cytochrome P450 enzyme
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Astex raises an additional £5.7m ($8.1m)
(Astex Technology Ltd, 17 December)
http://pharmalicensing.com/company/disprelease/1008687426_3c1f59428de21
Astex Technology, the structure-based drug discovery company
pioneering the use of high throughput X-ray crystallography (HTX(tm))
technology, today announced the receipt of a further £5.7m
($8.1m) from its current investors: Abingworth, Advent
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GlobeTech successfully beta tested a new solution to the rx parallel
trade problem
(Global Technologies, 15 December)
http://pharmalicensing.com/company/disprelease/1008445916_3c1ba9dcbb76f
GlobeTech successfully beta tested its GT1 market modeling technology
on a major drug and five European markets
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pharmexa subsidiary Inoxell announces achievement of first milestone in
a collaboration with AstraZeneca
(Pharmexa A/S, 14 December)
http://pharmalicensing.com/company/disprelease/1008325869_3c19d4ed942ab
Pharmexa's 83,3% owned subsidiary Inoxell A/S and AstraZeneca
announce achievement of the first milestone in the evaluation of
Inoxell's patented CellScreen technology, to rapidly identify
potential drug targets.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Life Saving Therapy for "HIV/AIDS"
(Endocrine Transplant, Inc, 13 December)
http://pharmalicensing.com/company/disprelease/1008224011_3c18470b77b42
A drug to inhibit HIV immunopathogenesis and stimulate human immunity
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ATHERSYS TO PROVIDE PFIZER WITH DRUG TARGETS
(Athersys, Inc., 13 December)
http://pharmalicensing.com/company/disprelease/1008256599_3c18c657cffd1
Athersys Inc. has entered into a drug discovery collaboration with
Pfizer (NYSE: PFE) to provide cell lines expressing protein drug
targets.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Do you want your company news to reach thousands of licensing and
business development professionals? Contact us at
sales@pharmalicensing.com to find out more.
-----------------------------------------------------------------------
| Need to know the latest news in pharma/biotech partnering?
|
| Pharmalicensing Update - Business Development Report
|
| December issue out now - view the contents page
|
| http://pharmalicensing.com/features/disp/1003401396_3bceb0b4c7eae
|
| Our new monthly report will keep you up to date on the latest
| partnering developments and opportunities.
|
| http://pharmalicensing.com/features/disp/1003401396_3bceb0b4c7eae
|
| Subscribe today to receive 15 issues for the price of 12 !!
| Offer ends 31st December 2001
-----------------------------------------------------------------------
INDUSTRY NEWS
A selection of stories from our news service, focusing on important
licensing and business development news.
AHP and Elan create alliance for treatment of sleep disorders
http://pharmalicensing.com/news/index/1008924180_3c22f61470f6b
NeoTherapeutics signs second license agreement with Pfizer
http://pharmalicensing.com/news/index/1008924175_3c22f60f22d1e
MorphoSys and Schering form strategic alliance
http://pharmalicensing.com/news/index/1008924170_3c22f60a49dd4
Sanofi-Synthelabo and Cephalon sign collaboration agreement
http://pharmalicensing.com/news/index/1008924169_3c22f60944f9f
PhotoCure licenses Metvix to Galderma
http://pharmalicensing.com/news/index/1008924169_3c22f609dc58e
Dynavax and Triangle Announce Positive Hepatitis B Prophylaxis Data
http://pharmalicensing.com/news/index/1008694552_3c1f75185a006
Pharmacopeia and Locomogene Form Research Collaboration
http://pharmalicensing.com/news/index/1008694550_3c1f751692264
Vical Licenses Poloxamer Technology From CytRx
http://pharmalicensing.com/news/index/1008694541_3c1f750dca44c
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Use our alerts to get daily news: log in to the site and choose
"Email alerting preferences" from your User Centre.
Got a story? Tell our editors about it by sending mail to
editors@pharmalicensing.com
-----------------------------------------------------------------------
EVENTS AND CONFERENCES
Pharmalicensing brings you the best in conferences from the cutting
edge of pharmaceutical and biotech business.
Biobusiness 2002- The Premier Global Bio-Partnering Conference
(Worldwide Business Research)
22 Jan - 24 Jan 2002 - Geneva, Switzerland
BioBusiness 2002 will take a step back and look at innovative methods
of discovering and developing a drug in today's industry. With a
specific emphasison pioneering partnership strategies between
biotechs and pharmas, we will also address effective licensing
techniques, creative financing methods and effective corporate
restructuring.
** Conference details available online at:
** http://pharmalicensing.com/events/disp/1002918545_3bc752919afa2
Contact: email: biobusiness@wbr.co.uk phone: +44 20 7759 9000
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Personalised medicine (IBC Life Sciences)
23 Jan - 25 Jan 2002 - San Francisco, CA, USA
The future of medicine is the availability of genomics to identify
individual predispositions to disease and apply an ever-increasing
variety of pharmaceutical and nutritional products to preserve
individual health and wellness. This future will be driven not only
by advances in technology, but also by consumer demand for
'personalized' rather than 'managed' care.
** Conference details available online at:
** http://pharmalicensing.com/events/disp/1003747703_3bd3f9778e5a7
Contact: email: reg@ibcusa.com phone: +1 (508) 616-5550
Online registration available at:
http://www.lifesciencesinfo.com/persmed
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12th European Pharma License Exchange Meeting (RauCon .Com concepts +
competence)
27 Feb - 28 Feb 2002 - Nice, France
This License Business Meeting will focus on generic drugs,
generics-plus (reformulated generics), bio-generics, and OTC products
as well as dietary supplements. It will also consider technologies
which can be applied to these items, e.g. drug delivery,
reformulation, and others
** Conference details available online at:
** http://pharmalicensing.com/events/disp/1004027948_3bd8402cbe97e
Contact: email: info@raucon.com phone: +49 6222 9807-0
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Full event calendar available online:
December http://pharmalicensing.com/events/calendar/122001
January http://pharmalicensing.com/events/calendar/012002
February http://pharmalicensing.com/events/calendar/022002
You can now sign up for email alerts of upcoming events and
conferences. Log in to the site, click "User centre" then "Email
alerting preferences".
Want your events featured on the site? Send free entries to
editor@pharmalicensing.com or contact us at sales@pharmalicensing.com
for details of full event advertising and promotion.
-----------------------------------------------------------------------
ENDNOTES
Feedback -- please send comments or suggestions about this newsletter
to feedback@pharmalicensing.com.
Advertising -- for details of advertising and sponsorship opportunities
on this newsletter or the pharmalicensing.com web site, please contact
us at sales@pharmalicensing.com.
Reproduction -- feel free to forward and redistribute this newsletter.
We ask that all reproductions be credited as follows:
Copyright (C) 2001 Pharmalicensing Ltd
Disclaimer -- while Pharmalicensing Ltd and its agents used their best
efforts in collecting and preparing the information published herein,
we do not assume, and hereby disclaim, any liability for any loss or
damage caused by errors or omissions, whether such errors or omissions
resulted from negligence, accident or other causes.
Contact -- info@pharmalicensing.com. Pharmalicensing Ltd, KL House 1st
Floor, Kettlestring Lane, Clifton Moor, York, YO30 4XF, United Kingdom
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .